-
MPC, Lactate, and Histone Lactylation in CRC
2026-08-13
The reference study identifies mitochondrial pyruvate carrier loss as a driver of lactate accumulation, histone lactylation, dendritic-cell dysfunction, and weaker CD8+ T-cell responses in colorectal cancer. Its integrated genetic, cellular, animal, and immunotherapy experiments position MPC as a metabolic–epigenetic checkpoint with potential relevance to tumor-microenvironment research.
-
DAPI Nuclear Stain Solution Protocol
2026-08-13
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution K2402 provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint cell viability assessment. It is best suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, not primary live-cell imaging.
-
EZ Cap EGFP mRNA 5-moUTP as a Delivery Readout
2026-08-12
EZ Cap EGFP mRNA 5-moUTP can function as more than an EGFP reporter: it is a practical probe for separating delivery, intracellular release, and translation. This article connects transcript architecture with redox-responsive coacervate research to improve mRNA delivery for gene expression studies.
-
Y-27632 Dihydrochloride for Organoid Workflows
2026-08-12
Use Y-27632 dihydrochloride as a controlled ROCK inhibitor for improving post-dissociation recovery, resolving cytoskeletal phenotypes, and testing metastatic organoid behavior. This workflow connects practical cell handling with the lineage-plasticity framework emerging from colorectal cancer research while separating established product properties from assay-specific optimization.
-
AGO1, Protein Folding, and Stem Cell Fate
2026-08-11
The 2024 Developmental Cell study identifies an RNA-independent role for AGO1 in maintaining mouse embryonic stem cell self-renewal. By linking AGO1 to the HOP chaperone complex and folding of intrinsically disordered transcription factors, it establishes protein proteostasis as a previously underappreciated regulator of stem cell fate.
-
Proteasome Control in Viral Necroptosis Research
2026-08-11
A translational framework for using Clasto-Lactacystin β-lactone to test proteasome dependence in RIPK3 degradation, necroptosis, and virus-induced inflammation. The article connects the ubiquitin-proteasome pathway to viral immune evasion while defining practical controls, product-handling considerations, and the limits of chemical perturbation.
-
Dutasteride Workflows for Prostate Research
2026-08-10
Dutasteride combines dual 5-alpha-reductase inhibition with measurable androgen-pathway and apoptosis readouts, making it useful for mechanism-driven prostate cancer and benign prostatic hyperplasia research. This guide translates target engagement into practical cell-based workflows, controls, troubleshooting strategies, and a carefully bounded cross-domain lesson from hepatic ischemia–reperfusion research.
-
Separating Growth Inhibition from Cell Death
2026-08-09
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a time-aware framework for distinguishing proliferative arrest from actual cell killing, improving interpretation of in vitro drug-response experiments.
-
Abiraterone acetate in Reliable Viability Assays
2026-08-08
Learn how Abiraterone acetate (SKU A8202) can support reproducible prostate cancer viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects CYP17 biology with solvent handling, 3D spheroid interpretation, assay controls, and practical product selection.
-
Muscle-Derived BDNF and MMPs Orchestrate Early NMJ Assembly
2026-08-07
This study demonstrates that muscle-generated BDNF, trafficked and released in a spatially restricted, activity-dependent manner, is crucial for the initial formation of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. By dissecting the roles of proteolytic processing—particularly MMP-mediated conversion—the work provides a mechanistic framework for understanding early synaptic differentiation and offers practical pathways for targeted experimental intervention.
-
Leucomycin (kitasamycin): Applied Workflows & Troubleshootin
2026-08-06
Leucomycin (kitasamycin) from APExBIO empowers translational inhibition, antibacterial discovery, and resistance profiling with robust performance in demanding assay conditions. This guide distills advanced workflow recommendations, protocol parameters, and troubleshooting strategies to maximize reliability and reproducibility in macrolide antibiotic research.
-
MK-5108: Precision Aurora A Inhibition in Retinoblastoma Mod
2026-08-06
MK-5108 (VX-689) delivers nanomolar-selective Aurora A inhibition, enabling targeted cell cycle disruption in cancer research. This guide translates recent retinoblastoma breakthroughs into practical protocols, troubleshooting steps, and advanced applications for scientists seeking robust, reproducible results.
-
AZD1390: Precision ATM Inhibition for Advanced DNA Repair Re
2026-08-05
This thought-leadership article explores how the next-generation ATM kinase inhibitor AZD1390 enables translational researchers to dissect DNA double-strand break (DSB) repair, optimize radiosensitization in glioma and lung cancer, and probe the interplay between the DNA damage response and G-quadruplex DNA replication stress. Blending mechanistic insights with practical workflow guidance, it uniquely bridges the latest discoveries in the REV1–DHX36 G4 tolerance pathway with the strategic deployment of AZD1390 in cancer models, offering a forward-looking perspective for precision oncology.
-
Uridine, Trisodium Salt: Advanced Workflows for RNA Biosynth
2026-08-05
Uridine, Trisodium Salt (APExBIO) sets a new benchmark for RNA biosynthesis and site-specific genome engineering workflows. This ultra-pure nucleoside analog supports both high-fidelity RNA template construction and vascular biology research, with quantifiable advantages for reproducibility and efficiency in PRINT-based transgene insertion.
-
Carrier-Free Triterpene Prodrug Platform for OSCC Chemothera
2026-08-04
This study introduces a novel carrier-free, self-assembled triterpene-based prodrug system for oral squamous cell carcinoma (OSCC) chemotherapy. By leveraging ROS-responsive linkers and supramolecular assembly of natural products, the research demonstrates targeted, self-boosted drug release with enhanced tumor specificity and reduced systemic toxicity.